Cargando…
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19–FGFR4 signal...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627123/ https://www.ncbi.nlm.nih.gov/pubmed/31167419 http://dx.doi.org/10.3390/cells8060536 |
_version_ | 1783434665517907968 |
---|---|
author | Raja, Aroosha Park, Inkeun Haq, Farhan Ahn, Sung-Min |
author_facet | Raja, Aroosha Park, Inkeun Haq, Farhan Ahn, Sung-Min |
author_sort | Raja, Aroosha |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19–FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1–4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors. |
format | Online Article Text |
id | pubmed-6627123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66271232019-07-19 FGF19–FGFR4 Signaling in Hepatocellular Carcinoma Raja, Aroosha Park, Inkeun Haq, Farhan Ahn, Sung-Min Cells Review Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19–FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1–4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors. MDPI 2019-06-04 /pmc/articles/PMC6627123/ /pubmed/31167419 http://dx.doi.org/10.3390/cells8060536 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Raja, Aroosha Park, Inkeun Haq, Farhan Ahn, Sung-Min FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title | FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title_full | FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title_fullStr | FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title_full_unstemmed | FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title_short | FGF19–FGFR4 Signaling in Hepatocellular Carcinoma |
title_sort | fgf19–fgfr4 signaling in hepatocellular carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627123/ https://www.ncbi.nlm.nih.gov/pubmed/31167419 http://dx.doi.org/10.3390/cells8060536 |
work_keys_str_mv | AT rajaaroosha fgf19fgfr4signalinginhepatocellularcarcinoma AT parkinkeun fgf19fgfr4signalinginhepatocellularcarcinoma AT haqfarhan fgf19fgfr4signalinginhepatocellularcarcinoma AT ahnsungmin fgf19fgfr4signalinginhepatocellularcarcinoma |